Chemical formula: C₅₆H₇₁N₉O₂₃S Molecular mass: 1,270.274 g/mol PubChem compound: 477468
Micafungin is indicated for:
Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)
Treatment of invasive candidiasis.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)
Treatment of oesophageal candidiasis in patients for whom intravenous therapy is appropriate.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)
Prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count <500 cells/µl) for 10 or more days.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only children (1 year - 12 years old)
Treatment of invasive candidiasis.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only children (1 year - 12 years old)
Prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count <500 cells/µl) for 10 or more days.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only newborns (0 - 40 days old) , infants (40 days - 1 year old)
Treatment of invasive candidiasis.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only newborns (0 - 40 days old) , infants (40 days - 1 year old)
Prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count <500 cells/µl) for 10 or more days.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
